Chronic nerve pain affects a growing share of the global population, and the treatment landscape is evolving rapidly to keep pace. A recent neuropathic pain market report values the global industry at USD 7.81 billion in 2023, projecting growth to USD 8.33 billion in 2024 and further to roughly USD 14.10 billion by 2031, representing a compound annual growth rate of approximately 7.81 percent. That expansion is being fueled by the rising global burden of diabetes, cancer, and other chronic conditions that damage nerve tissue, combined with a wave of drug and device innovation aimed squarely at reducing reliance on opioid-based pain management.
Understanding the Market
Neuropathic pain arises from nerve damage or dysfunction linked to conditions such as diabetes, shingles, multiple sclerosis, spinal cord injury, and chemotherapy. The market encompasses both pharmaceutical interventions—anticonvulsants, antidepressants, opioids, and topical treatments—and non-pharmacological approaches including neuromodulation, physical therapy, and regenerative medicine. Major companies active in the space include Sun Pharmaceutical Industries, Novartis, Abbott, Pfizer, Grünenthal, Eli Lilly, Glenmark Pharmaceuticals, Vertex Pharmaceuticals, and Collegium Pharmaceutical, reflecting a competitive field that spans both large multinational pharma and specialized pain-management innovators.
An aging global population is compounding demand, since older adults are considerably more susceptible to nerve-related pain disorders. At the same time, growing investment in regenerative medicine and gene therapy is opening the door to longer-term solutions that go beyond symptom management, while digital health tools—including AI-powered pain management platforms and remote monitoring—are helping clinicians personalize treatment and track outcomes more effectively.
Key highlight: North America held nearly half the global market in 2023, at 49.94 percent share and a valuation of USD 3.90 billion, while diabetic neuropathy alone accounted for roughly 49.39 percent of the market by indication.
Growth Driver: The Chronic Disease Burden
The rising global incidence of diabetes and other chronic conditions that contribute to nerve damage is the market’s primary growth engine. Pharmaceutical companies are responding with combination therapies designed to target multiple pain pathways simultaneously, improving efficacy over single-mechanism treatments. Regulatory approvals for these novel formulations are accelerating adoption, and rising awareness among both clinicians and patients is further supporting uptake. In February 2023, for instance, Anglo-French Drugs & Industries launched AFD-NP, a combination of nortriptyline and pregabalin specifically targeting moderate to severe neuropathic pain, addressing the growing burden of diabetes-related nerve pain following approval from the Drug Control Department.
Challenge: Efficacy and the Opioid Question
Despite steady innovation, the market continues to grapple with a persistent challenge: many existing drug therapies deliver only partial pain relief while causing meaningful side effects, including dizziness, drowsiness, and gastrointestinal discomfort. Long-term opioid use raises additional concerns around dependency and regulatory scrutiny, complicating treatment decisions for both physicians and patients. The industry’s response has centered on advancing non-pharmacological and precision-medicine approaches—including neuromodulation therapies and novel drug formulations engineered for improved safety profiles—alongside growing investment in biologics, gene therapy, and non-invasive nerve stimulation technologies.
Trend: The Shift Toward Non-Invasive Treatment
One of the clearest trends reshaping the market is the pivot toward non-invasive and non-pharmacological treatment options. Rising concern over the long-term risks of pharmacological treatment, particularly for conditions like painful diabetic neuropathy, has fueled interest in peripheral nerve stimulation and neuromodulation techniques that offer effective relief with fewer side effects. In January 2024, Neuralace Medical received FDA clearance for Axon Therapy, the first non-invasive magnetic peripheral nerve stimulation treatment for painful diabetic neuropathy, following a randomized controlled trial that demonstrated significant pain reduction. Regulatory validation of this kind is helping build clinician confidence and is expected to accelerate integration of non-invasive therapies into standard pain management protocols.
Segmentation Analysis
By Type
Anticonvulsants generated the largest revenue among drug types in 2023, at approximately USD 2.77 billion, reflecting their status as a first-line treatment for conditions such as diabetic neuropathy and postherpetic neuralgia.
By Indication
Diabetic neuropathy accounted for roughly 49.39 percent of the market in 2023 and is projected to reach approximately USD 7.12 billion by 2031, driven by the rising global prevalence of diabetes and increasing awareness around early diagnosis and management of associated nerve pain.
By Distribution Channel
Retail pharmacies are projected to lead distribution channels by 2031, reaching an estimated USD 7.19 billion in revenue as pharmacy networks expand in emerging economies and consumers increasingly favor the convenience and personalized consultation retail pharmacies provide.
Regional Outlook
North America dominated the global market in 2023, commanding a 49.94 percent share worth USD 3.90 billion. The region’s strength stems from a high prevalence of chronic conditions such as diabetes and cancer, combined with advanced healthcare infrastructure, strong R&D capabilities, and rapid uptake of novel pain-management therapies. In February 2025, Vistagen secured a U.S. patent—valid until at least 2034—for its oral non-opioid candidate AV-101, underscoring the region’s continued innovation pipeline around non-opioid alternatives.
Asia-Pacific is set to be the fastest-growing region through 2031, expanding at a projected CAGR of roughly 8.95 percent and reaching an estimated USD 2.68 billion by the end of the forecast period. Rising prevalence of diabetes and cancer, expanding pharmaceutical manufacturing capacity, and growing healthcare investment across China, India, and Japan are driving this growth, supported by government initiatives promoting affordable generic drugs and innovative therapies.
Regulatory Landscape
In the United States, the Food and Drug Administration regulates the approval, safety, and marketing of neuropathic pain medications and devices, ensuring antidepressants, anticonvulsants, NSAIDs, and opioids meet rigorous clinical standards. In Europe, the European Medicines Agency oversees pharmaceutical approval and safety monitoring at the regional level, working alongside national regulators to enforce consistent efficacy and safety requirements across member states.
Competitive Landscape
Competition in the neuropathic pain market centers on continuous R&D aimed at improving drug efficacy, minimizing side effects, and exploring novel therapeutic targets such as sodium channel blockers and monoclonal antibodies. In January 2025, Vertex Pharmaceuticals achieved a landmark FDA approval for JOURNAVX, a first-in-class non-opioid NaV1.8 pain signal inhibitor for moderate-to-severe acute pain—the first new class of pain medicine approved in more than two decades and a milestone that signals real momentum for opioid-free alternatives. That approval built on earlier progress: in April 2024, Vertex advanced its suzetrigine program with a rolling FDA submission for acute pain and Breakthrough Therapy designation specifically for diabetic peripheral neuropathy. Meanwhile, Grünenthal and Averitas Pharma completed Phase III trial recruitment for QUTENZA in post-surgical neuropathic pain in November 2024, with topline results expected in late 2025 and a submission planned for 2026.
As non-opioid drug classes clear regulatory hurdles and non-invasive neuromodulation devices gain broader clinical acceptance, the neuropathic pain market appears poised for a meaningful shift away from legacy pharmacological standards and toward a more diversified, technology-enabled treatment landscape.
Source data and detailed segmentation referenced from Kings Research’s neuropathic pain market report. This article is an independent editorial summary and analysis.
